420 related articles for article (PubMed ID: 29299596)
1. Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain.
Nakama K; Koga H; Ishii N; Ohata C; Hashimoto T; Nakama T
JAMA Dermatol; 2018 Mar; 154(3):347-350. PubMed ID: 29299596
[TBL] [Abstract][Full Text] [Related]
2. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
[TBL] [Abstract][Full Text] [Related]
3. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
Mai Y; Nishie W; Izumi K; Shimizu H
Front Immunol; 2019; 10():1224. PubMed ID: 31191560
[TBL] [Abstract][Full Text] [Related]
4. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the combination of BP180-NC16a enzyme-linked immunosorbent assay and BP230 enzyme-linked immunosorbent assay in the diagnosis of bullous pemphigoid.
Yang B; Wang C; Chen S; Chen X; Lu X; Tian H; Yu M; Zhang D; Shi Z; Zhou G; Zhang F
Indian J Dermatol Venereol Leprol; 2012; 78(6):722-7. PubMed ID: 23075641
[TBL] [Abstract][Full Text] [Related]
6. Normal human skin is superior to monkey oesophagus substrate for detection of circulating BP180-NC16A-specific IgG antibodies in bullous pemphigoid.
Emtenani S; Yuan H; Lin C; Pan M; Hundt JE; Schmidt E; Komorowski L; Stanley JR; Hammers CM
Br J Dermatol; 2019 May; 180(5):1099-1106. PubMed ID: 30315657
[TBL] [Abstract][Full Text] [Related]
7. Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients.
Mariotti F; Grosso F; Terracina M; Ruffelli M; Cordiali-Fei P; Sera F; Zambruno G; Mastrogiacomo A; Di Zenzo G
Br J Dermatol; 2004 Nov; 151(5):1004-10. PubMed ID: 15541078
[TBL] [Abstract][Full Text] [Related]
8. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients.
Charneux J; Lorin J; Vitry F; Antonicelli F; Reguiai Z; Barbe C; Tabary T; Grange F; Bernard P
Arch Dermatol; 2011 Mar; 147(3):286-91. PubMed ID: 21422334
[TBL] [Abstract][Full Text] [Related]
10. A case of bullous pemphigoid with IgG antibodies against LAD-1, but not BP180 NC16a domain or BP230.
Miyashita K; Iioka H; Miyagawa F; Ishii N; Hashimoto T; Asada H
Eur J Dermatol; 2018 Apr; 28(2):248-250. PubMed ID: 29378676
[No Abstract] [Full Text] [Related]
11. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid.
Sakuma-Oyama Y; Powell AM; Oyama N; Albert S; Bhogal BS; Black MM
Br J Dermatol; 2004 Jul; 151(1):126-31. PubMed ID: 15270881
[TBL] [Abstract][Full Text] [Related]
13. A case of bullous pemphigoid associated with autoantibodies targeting antigenic sites other than the NC16a domain of BP180.
Shinojima Y; Ochiai T; Kawamura A; Arakawa H; Fukuda K; Hashimoto T
Clin Exp Dermatol; 2005 Sep; 30(5):503-5. PubMed ID: 16045678
[TBL] [Abstract][Full Text] [Related]
14. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.
Döpp R; Schmidt E; Chimanovitch I; Leverkus M; Bröcker EB; Zillikens D
J Am Acad Dermatol; 2000 Apr; 42(4):577-83. PubMed ID: 10727301
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunological profiles of anti-BP230-type bullous pemphigoid: Restriction of epitopes to the C-terminal domain of BP230, shown by novel ELISAs of BP230-domain specific recombinant proteins.
Hayakawa T; Teye K; Hachiya T; Uehara R; Hashiguchi M; Kawakami T; Li X; Tsuchisaka A; Ohara K; Sogame R; Koga H; Hamada T; Ohata C; Furumura M; Ishii N; Fukano H; Shimozato K; Hashimoto T
Eur J Dermatol; 2016 Apr; 26(2):155-63. PubMed ID: 27087683
[TBL] [Abstract][Full Text] [Related]
16. Missing the target: characterization of bullous pemphigoid patients who are negative using the BP180 enzyme-linked immunosorbant assay.
Fairley JA; Bream M; Fullenkamp C; Syrbu S; Chen M; Messingham KN
J Am Acad Dermatol; 2013 Mar; 68(3):395-403. PubMed ID: 23083837
[TBL] [Abstract][Full Text] [Related]
17. Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid.
Bing L; Xiping Z; Li L; Jun P; Yi-Xia W; Min Y; Qing L; Qiu-Ning S; Hong-Zhong J; Ya-Gang Z
Arch Dermatol Res; 2015 Nov; 307(9):849-54. PubMed ID: 26404084
[TBL] [Abstract][Full Text] [Related]
18. Anti-BP180 Autoantibodies Are Present in Stroke and Recognize Human Cutaneous BP180 and BP180-NC16A.
Wang Y; Mao X; Wang D; Hammers CM; Payne AS; Wang Y; Jin H; Peng B; Li L
Front Immunol; 2019; 10():236. PubMed ID: 30863396
[No Abstract] [Full Text] [Related]
19. Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid.
Sadik CD; Langan EA; Grätz V; Zillikens D; Terheyden P
Front Immunol; 2019; 10():1934. PubMed ID: 31474998
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study.
Fichel F; Barbe C; Joly P; Bedane C; Vabres P; Truchetet F; Aubin F; Michel C; Jegou J; Grange F; Antonicelli F; Bernard P
JAMA Dermatol; 2014 Jan; 150(1):25-33. PubMed ID: 24226428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
